IAC vs NBIX · P/E 26, rev $3.81B vs P/E 45, rev $2.36B
IAC Inc. (IAC) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
IAC Inc. (IAC) is a internet content & information company listed on NASDAQ.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Latest reported IAC revenue for 2024-12-31 was $3.81B. Net income was -$533.3M. Revenue was down 12.8% from 2023-12-31 to 2024-12-31. IAC currently screens at market cap $3.14B and trailing P/E 25.9.
Latest reported NBIX revenue for 2024-12-31 was $2.36B. Net income was $341.3M. Revenue was up 24.8% from 2023-12-31 to 2024-12-31. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
IAC currently screens at market cap $3.14B and trailing P/E 25.9. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the IAC and NBIX stock pages for the full models.
Not investment advice.